Evidence map›Paper›PMID 37251950›Full record

ArticleFrontiers in oncology2023

A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer.

Gelareh Vahabzadeh, Solmaz Khalighfard, Ali Mohammad Alizadeh, Mahsa Yaghobinejad, Mahta Mardani, Tayebeh Rastegar, Mahmood Barati, Morad Roudbaraki, Ebrahim Esmati, Mohammad Babaei and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Radiotherapy effects on the ceRNA network in high-risk prostate cancer patients.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Gelareh VahabzadehRazi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.
Solmaz KhalighfardResearch Center on Developing Advanced Technologies, Tehran, Iran.
Ali Mohammad AlizadehCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mahsa YaghobinejadDepartment of Anatomy, School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
Mahta MardaniCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Tayebeh RastegarDepartment of Anatomy, School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
Mahmood BaratiDepartment of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Morad RoudbarakiLaboratory of Cell Physiology, Inserm U1003, University of Lille, Villeneuve d'Ascq, France.
Ebrahim EsmatiRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad BabaeiRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ali KazemianRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRIran University of Medical Sciences · IRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The present study aimed to investigate the interaction of the common lncRNA-miRNA-mRNA network involved in signaling pathways in different stages of prostate cancer (PCa) by using bioinformatics and experimental methods. Methods: Seventy subjects included sixty PCa patients in Local, Locally Advanced, Biochemical Relapse, Metastatic, and Benign stages, and ten healthy subjects were entered into the current study. The mRNAs with significant expression differences were first found using the GEO database. The candidate hub genes were then identified by analyzing Cytohubba and MCODE software. Cytoscape, GO Term, and KEGG software determined hub genes and critical pathways. The expression of candidate lncRNAs, miRNAs, and mRNAs was then assessed using Real-Time PCR and ELISA techniques. Results: 4 lncRNAs, 5 miRNAs, and 15 common target genes were detected in PCa patients compared with the healthy group. Unlike the tumor suppressors, the expression levels of common onco-lncRNAs, oncomiRNAs, and oncogenes showed a considerable increase in patients with advanced stages; Biochemical Relapse and Metastatic, in comparison to the primary stages; Local and Locally Advanced. Additionally, their expression levels significantly increased with a higher Gleason score than a lower one. Conclusion: Identifying a common lncRNA-miRNA-mRNA network associated with prostate cancer may be clinically valuable as potential predictive biomarkers. They can also serve as novel therapeutic targets for PCa patients.

Indexed as

biomarkersGleasonnetworkprostate cancerPSA

Identifiers

PMID37251950
PMCPMC10215985
OpenAlexW4375864392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.